Drugs / hCBE-11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00105170 | Jan 2005 → Aug 2006 | neoplasm | Biogen | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hCBE-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00105170 ↗ |
| Action | Activate | “Tumor necrosis factor receptor superfamily member 3 agonist” CHEMBL2109509 ↗ |
| Modality | Monoclonal antibody | “a Humanized Monoclonal Antibody” NCT00105170 ↗ |
| Target | LTBR | “Tumor necrosis factor receptor superfamily member 3 agonist” CHEMBL2109509 ↗ |